Business Description
Tarsus Pharmaceuticals Inc
NAICS : 541714
SIC : 2833
Description
Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03 is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.12 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.29 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 6.42 | |||||
| Beneish M-Score | -3.2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -10.3 | |||||
| 3-Year EPS without NRI Growth Rate | -8.4 | |||||
| 3-Year FCF Growth Rate | -7.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.96 | |||||
| 9-Day RSI | 54.57 | |||||
| 14-Day RSI | 51 | |||||
| 6-1 Month Momentum % | 43.19 | |||||
| 12-1 Month Momentum % | 7.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.43 | |||||
| Quick Ratio | 12.43 | |||||
| Cash Ratio | 12.07 | |||||
| Days Sales Outstanding | 18.62 | |||||
| Days Payable | 5601.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -124.5 | |||||
| Shareholder Yield % | -2.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.8 | |||||
| Operating Margin % | -765.92 | |||||
| Net Margin % | -727.62 | |||||
| ROE % | -48.47 | |||||
| ROA % | -40.7 | |||||
| ROIC % | -2589.69 | |||||
| ROC (Joel Greenblatt) % | -4251.11 | |||||
| ROCE % | -42.05 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 36.23 | |||||
| PB Ratio | 3.08 | |||||
| Price-to-Tangible-Book | 3.09 | |||||
| EV-to-EBIT | -4.51 | |||||
| EV-to-EBITDA | -4.54 | |||||
| EV-to-Revenue | 31.82 | |||||
| EV-to-Forward-Revenue | 7.97 | |||||
| EV-to-FCF | -5.19 | |||||
| Price-to-Net-Current-Asset-Value | 3.2 | |||||
| Price-to-Net-Cash | 3.33 | |||||
| Earnings Yield (Greenblatt) % | -22.17 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TARS
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tarsus Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 12.5 | ||
| EPS (TTM) ($) | -3.38 | ||
| Beta | 0 | ||
| Volatility % | 49.5 | ||
| 14-Day RSI | 51 | ||
| 14-Day ATR ($) | 0.908922 | ||
| 20-Day SMA ($) | 16.5575 | ||
| 12-1 Month Momentum % | 7.55 | ||
| 52-Week Range ($) | 11.33 - 25.25 | ||
| Shares Outstanding (Mil) | 32.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tarsus Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tarsus Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tarsus Pharmaceuticals Inc Frequently Asked Questions
What is Tarsus Pharmaceuticals Inc(TARS)'s stock price today?
The current price of TARS is $16.95. The 52 week high of TARS is $25.25 and 52 week low is $11.33.
When is next earnings date of Tarsus Pharmaceuticals Inc(TARS)?
The next earnings date of Tarsus Pharmaceuticals Inc(TARS) is 2023-11-09 Est..
Does Tarsus Pharmaceuticals Inc(TARS) pay dividends? If so, how much?
Tarsus Pharmaceuticals Inc(TARS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers